Skip to main content
A scary good deal on trusted journalism
Get full digital access to globeandmail.com
$0.99
per week for 24 weeks SAVE OVER $140
OFFER ENDS OCTOBER 31
A scary good deal on trusted journalism
$0.99
per week
for 24 weeks
SAVE OVER $140
OFFER ENDS OCTOBER 31
Start Today
// //
Flash Sale $0.99/24 weeks
Register
AdChoices

Regeneron Pharmaceuticals NASDAQ: REGN-Q

Today's Change
Volume
Real-Time Last Update Last Sale Cboe BZX Real-Time
Alerts Watchlist Portfolio

Today's Trading

Day Low 565.39
Day High 573.01
Open:570.03
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Latest
inside the market
Market movers: Stocks that saw action on Tuesday - and why
Subscriber content
number cruncher
These 10 U.S. large-cap stocks demonstrate consistent, solid profitability
Subscriber content
number cruncher
These 15 U.S. stocks with growing profits also score well on ESG risk
Subscriber content
inside the market
Market movers: Stocks that saw action on Monday - and why
Subscriber content
investment ideas
Renewable energy, pot stocks top losers as election results leave Wall Street hanging
u.s. business
Eli Lilly pauses trial of antibody drug Trump touted as COVID-19 ‘cure’ over safety concern
Subscriber content
Description
Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma and has preclinical programs in other diseases and disorders.

Fundamentals

Market Capitalization, $K
Shares Outstanding, K
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

View Earnings zacks

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.

Moderate Buy
View Estimates zacks

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

Download Premium PDF Refinitiv. Trademark. Data is Just the Beginning.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

Download Premium PDF StockCalc

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Download Free PDF ValueEngine logo

Latest Press Releases

More Stories
Second Dupixent® (dupilumab) Phase 3 Eosinophilic Esophagitis Trial to Demonstrate Significant Disease Improvements, Underscoring Role of Type 2 Inflammation in This Complex Disease
PR Newswire - Sun Oct 24, 11:59PM CDT
PR Newswire - PRTGAM
Sun Oct 24, 11:59PM CDT
/PRNewswire/ -- Dupixent 300 mg weekly significantly improved the ability to swallow and reduced eosinophils in the esophagus compared to placebo, reinforcing...
Dupixent® (dupilumab) is the First Biologic to Significantly Reduce Itch and Skin Lesions in Phase 3 Trial for Prurigo Nodularis, Demonstrating the Role of Type 2 Inflammation in this Disease
PR Newswire - Thu Oct 21, 11:59PM CDT
PR Newswire - PRTGAM
Thu Oct 21, 11:59PM CDT
/PRNewswire/ -- Pivotal trial met primary and all key secondary endpoints Dupixent significantly reduced itch at 12 weeks, and nearly three times as many...
FDA Expands Approval of Dupixent® (dupilumab) to Include Children Aged 6 to 11 Years with Moderate-to-severe Asthma
PR Newswire - Wed Oct 20, 4:29PM CDT
PR Newswire - PRTGAM
Wed Oct 20, 4:29PM CDT
/PRNewswire/ -- Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting...
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 539.18 +6.15% increase
on 10/18/21
Period Open:647.06
Price movement based on the high, low and last over the given period.
655.00 -12.62% decrease
on 09/23/21
 -74.70 (-11.54%) decrease
since 09/22/21
3-Month 539.18 +6.15% increase
on 10/18/21
Period Open:586.88
Price movement based on the high, low and last over the given period.
686.62 -16.64% decrease
on 09/03/21
 -14.52 (-2.47%) decrease
since 07/22/21
52-Week 441.00 +29.79% increase
on 03/04/21
Period Open:575.73
Price movement based on the high, low and last over the given period.
686.62 -16.64% decrease
on 09/03/21
 -3.37 (-0.59%) decrease
since 10/22/20

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

© 2021 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies